# Rovadicitinib是一種口服藥物，同時針對發炎和組織疤痕。

*biotech · news · 2026-03-03 · Reuters*

## Key points

- 中國生物製藥子公司將授予賽諾菲rovadicitinib的全球獨家權利。
- 賽諾菲將為rovadicitinib權利支付1.35億美元的前期費用。
- 中國生物製藥可能獲得最高達14億美元的里程碑付款。
- Rovadicitinib作為雙重作用口服藥物，針對發炎和組織疤痕。
- 授權協議需在完成前取得監管批准。

Under the agreement, Sino Biopharmaceutical's subsidiary ​Chia Tai Tianqing Pharmaceutical Group will grant ​Sanofi an exclusive worldwide licence to develop, manufacture and commercialise rovadicitinib, receiving an upfront payment ​of $135 million. Sign up here. The company is also ​eligible to receive potential development, regulatory and sales ‌milestone ⁠payments of up to $1.40 billion. Rovadicitinib is an oral drug that simultaneously targets inflammation and tissue scarring, two hallmarks ​of ​the diseases ⁠it is designed to treat. It belongs to a class ​of drugs known as JAK/ROCK ​inhibitors, ⁠which work by blocking enzymes that drive both processes. The deal is subject ⁠to ​customary closing conditions, including ​regulatory clearances, Sino Biopharmaceutical said. Reporting by Shivangi Lahiri ​in Bengaluru; Editing by Tasim Zahid

**Companies:** Sanofi, Sino Biopharmaceutical
**Countries:** China, France, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/sino-biopharm-unit-licenses-blood-cancer-drug-sanofi-up-153-bln-2026-03-03/)

---

Canonical: https://newsio.io/zh-TW/n/7f419c22-c48b-416e-828b-1c586abd324c/rovadicitinibjakrock
Summarized by Newsio from Reuters. https://newsio.io/how-it-works